Log in or Sign up for Free to view tailored content for your specialty!
Adrenal News
FDA grants priority review to crinecerfont for treatment of congenital adrenal hyperplasia
The FDA has granted priority review designation for two new drug applications for a selective corticotropin-releasing factor type 1 receptor to treat congenital adrenal hyperplasia, according to a press release.
Hypercortisolism prevalent among 24% of adults with difficult-to-control type 2 diabetes
ORLANDO — Nearly one-quarter of adults with difficult-to-control type 2 diabetes also have hypercortisolism, and treating hypercortisolism may also benefit glycemic control in those with both conditions, according to speakers.
Relacorilant tied to sustained cardiometabolic improvements in Cushing’s syndrome
PHILADELPHIA — Adults with Cushing’s syndrome who responded to relacorilant had sustained improvements in blood pressure and glucose levels through 34 weeks, according to findings from a phase 3 trial.
Log in or Sign up for Free to view tailored content for your specialty!
VIDEO: Data shed new light on treatments for acromegaly, Cushing’s disease
BOSTON — In this video exclusive, Maria Fleseriu, MD, FACE, discusses some of the top adrenal and pituitary news from ENDO 2024.
VIDEO: Possible game-changer for people with congenital adrenal hyperplasia
BOSTON —In this video exclusive, Richard J. Auchus, MD, PhD, describes a possible new treatment paradigm for congenital adrenal hyperplasia with crinecerfont, an investigational drug granted a breakthrough designation in December.
Mental health, sexual function worsen for men in first year of quitting steroids
BOSTON — In the first year after stopping anabolic steroid misuse, men had worse sexual function than those who continued using or never used the agents as well as more depression and anxiety, according to a presenter at ENDO 2024.
Oral therapy cuts androstenedione levels for children with congenital adrenal hyperplasia
BOSTON — Crinecerfont lowered androstenedione levels and allowed for lower glucocorticoid doses for children with classic congenital adrenal hyperplasia, according to findings from the CAHtalyst Pediatric phase 3 trial.
Oral nonsteroidal treatment ‘new paradigm’ for adults with congenital adrenal hyperplasia
BOSTON — Adults with congenital adrenal hyperplasia receiving an oral nonsteroidal treatment saw a marked reduction in daily glucocorticoid dose at 24 weeks with maintenance of androgen control compared with placebo, researchers reported.
New joint guideline focuses on treatment of glucocorticoid-induced adrenal insufficiency
Glucocorticoid tapering, education and treatment of adrenal crisis are three of the main focuses of a new clinical practice guideline on glucocorticoid-induced adrenal insufficiency.
Bone quality may improve after adrenalectomy for mild autonomous cortisol secretion
NEW ORLEANS —A small group of adults with mild autonomous cortisol secretion had an increase in spine trabecular bone score following adrenalectomy, according to a speaker at the AACE annual meeting.
-
Headline News
‘The mind is medicine’: How virtual reality can cool bothersome hot flashes
September 18, 20244 min read -
Headline News
CDC: Close contact of Missouri bird flu case had symptoms but was not tested
September 17, 20242 min read -
Headline News
Metformin use may lower risk for long COVID in adults with type 2 diabetes
September 18, 20243 min read
-
Headline News
‘The mind is medicine’: How virtual reality can cool bothersome hot flashes
September 18, 20244 min read -
Headline News
CDC: Close contact of Missouri bird flu case had symptoms but was not tested
September 17, 20242 min read -
Headline News
Metformin use may lower risk for long COVID in adults with type 2 diabetes
September 18, 20243 min read